Artiva Biotherapeutics
- Company typePublic
- Founded2019
- HeadquartersSan Diego, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Artiva Biotherapeutics firmographics
Firmographics- Name
- Artiva Biotherapeutics
- Legal name
- Artiva Biotherapeutics, Inc.
- Website
- https://artivabio.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Artiva Biotherapeutics industry classification
Industry- Product category
- Allogeneic NK Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- NK Cell Therapies (HLAAABAD)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Artiva Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Artiva Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- AlloNK Therapeutic Revenue: Artiva is a clinical-stage biopharmaceutical company with no current revenue. The company is developing AlloNK for autoimmune diseases with a planned Phase 3 registrational trial in refractory rheumatoid arthritis (initiating 2026) and anticipated BLA submission in 2029. Cantor Fitzgerald projects a path to over $1 billion in annual revenue if approved.
- None - Pre-Revenue Stage: Artiva reported $0 revenue in FY2025 with a net loss of $83.9 million. The company is in clinical development stage with no commercialized products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Projected manufacturing cost of approximately $8,000 per patient treatment |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Artiva Biotherapeutics product offering
Product offeringCore offering
Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell-based therapies. Its lead product candidate, AlloNK (AB-101), is a non-genetically modified, cryopreserved NK cell therapy intended to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with B-cell targeted monoclonal antibodies (rituximab, obinutuzumab) to drive deep B-cell depletion in autoimmune diseases. The pipeline also includes CAR-NK candidates AB-205 (CD5-directed) and AB-201 (HER2-directed).
Product overview
Artiva Biotherapeutics is a clinical-stage biotechnology company developing a portfolio of allogeneic natural killer (NK) cell-based therapies. The core product is AlloNK® (AB-101), a non-genetically modified, cryopreserved NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with B-cell targeted monoclonal antibodies like rituximab or obinutuzumab. The company operates under a 'manufacturing-first' approach, leveraging a partnership with GC Cell Corporation for scalable production. Pipeline includes CAR-NK programs AB-205 (CD5-directed for hematologic malignancies) and AB-201 (HER2-directed for solid tumors). Current clinical focus is on autoimmune diseases including rheumatoid arthritis, Sjögren's disease, systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
Differentiator
Problem solved
Functional benefit
Brands
- AlloNK: Non-genetically modified, cryopreserved NK cell therapy candidate being evaluated in combination with B-cell targeted monoclonal antibodies for autoimmune diseases. Also known as AB-101.
- AB-101
- AB-205
- AB-201
Products and services
- AlloNK (AB-101)
- AB-205 (CD5-Directed CAR-NK)
- AB-201 (HER2 CAR-NK)
Quantifiable outcome
- 71% of refractory RA patients achieved ACR50 response at six months in Phase 2a trial (21 patients)
- +4 more outcomes
Companies that use Artiva Biotherapeutics
Customer profileNamed customers1 record
Segments7 records
Ideal customer profiles3 records
Artiva Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Artiva Biotherapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major and core.
- IRIS (Investigator-Initiated Trial Partner)majorIRIS, a large community practice rheumatology clinic in Florida, submitted an IND to FDA for a basket investigator-initiated trial (NCT06581562) assessing AlloNK in combination with rituximab for RA, pemphigus vulgaris, SLE, and ANCA-associated vasculitis (GPA/MPA).
- GC Cell CorporationcoreStrategic manufacturing partner providing access to state-of-the-art cell therapy research and cGMP manufacturing facilities in Seoul, Korea. GC Cell is a subsidiary of GC Holdings. The partnership leverages over a decade's work by GC Cell in NK cell expansion technology. GC Cell holds ex-APAC rights to all Artiva programs. Total rights to programs held by Artiva ex-APAC.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Artiva Biotherapeutics competitors and assessment
Company assessmentBroad incumbents
- Adaptimmune Therapeutics: Adaptimmune is developing engineered T-cell therapies (SPEAR T-cells) for solid tumors with a recently approved product. Adjacent cell therapy space with overlapping manufacturing and regulatory know-how though autologous rather than allogeneic.
- Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage oncology programs. Less direct overlap given oncology focus, but shares the allogeneic off-the-shelf cell therapy platform approach and manufacturing infrastructure.
- Vertex Pharmaceuticals (VX-880/ImmunoQure/ Alpine acquisition): Vertex is developing cell therapies for type 1 diabetes and other indications, and through Alpine Immune Sciences has lupus nephritis programs. Large-cap incumbent with growing autoimmune cell therapy footprint that competes for share of voice in autoimmune space.
Emerging players
- Century Therapeutics: Century is developing iPSC-derived allogeneic cell therapies including NK and T cell programs. Comparable platform-level technology with similar off-the-shelf manufacturing ambition though earlier-stage clinical pipeline.
- Senti Biosciences: Senti Biosciences is developing gene circuit-engineered cell therapies including NK cell programs. Emerging player with comparable cell engineering approach though primarily oncology-focused.
- Caribou Biosciences: Caribou is developing allogeneic CAR-T and CAR-NK cell therapies using CRISPR-based genome editing. Comparable allogeneic platform technology, though primarily focused on hematologic malignancies with emerging autoimmune interest.
Direct peers
- Kyverna Therapeutics: Kyverna is developing CAR-T cell therapies (CD19) for autoimmune diseases including lupus nephritis, myositis, and MS. Competing head-to-head with Artiva in B-cell driven autoimmune indications using autologous CAR-T rather than allogeneic NK cells.
- Fate Therapeutics: Fate Therapeutics is a clinical-stage company developing off-the-shelf, iPSC-derived NK cell and T-cell therapies, including programs for autoimmune disease. Directly comparable to Artiva as both pursue allogeneic NK cell platforms with similar target indications and off-the-shelf manufacturing.
- Cabaletta Bio: Cabaletta Bio is developing CAR-T cell therapies (CD19, CD20) for autoimmune diseases including lupus, myositis, and RA. Direct competitor pursuing deep B-cell depletion in the same indications via a different cell therapy modality (T cells vs NK cells).
- Nkarta Therapeutics: Nkarta is developing allogeneic NK cell therapies engineered with CARs and membrane-bound IL-15 for autoimmune and oncology indications. Most directly comparable peer given overlapping NK cell approach, autoimmune focus, and allogeneic off-the-shelf model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Artiva Biotherapeutics social profiles
Digital presenceArtiva Biotherapeutics compliance and trust
Trust signalCompliance2 records
Artiva Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Artiva Biotherapeutics leadership team
Management profileNumber of profiles
Profiles9 records
Artiva Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors25 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Artiva Biotherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Artiva Biotherapeutics
What does Artiva Biotherapeutics do?
Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell-based therapies. Its lead product candidate, AlloNK (AB-101), is a non-genetically modified, cryopreserved NK cell therapy intended to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with B-cell targeted monoclonal antibodies (rituximab, obinutuzumab) to drive deep B-cell depletion in autoimmune diseases. The pipeline also includes CAR-NK candidates AB-205 (CD5-directed) and AB-201 (HER2-directed).
Is Artiva Biotherapeutics a public or private company?
Artiva Biotherapeutics is a public company. It is classified as public and is currently operating.
When was Artiva Biotherapeutics founded?
Artiva Biotherapeutics was founded in 2019. It employs 101 to 250 people.
Where is Artiva Biotherapeutics based?
Artiva Biotherapeutics is headquartered in San Diego, United States, in the North America region.
How does Artiva Biotherapeutics make money?
Two revenue lines are on record. AlloNK Therapeutic Revenue is the primary driver. The others are none - Pre-Revenue Stage.
Who are Artiva Biotherapeutics's main competitors?
Broad incumbents on record are Adaptimmune Therapeutics, Allogene Therapeutics and Vertex Pharmaceuticals (VX-880/ImmunoQure/ Alpine acquisition). Emerging players are Century Therapeutics, Senti Biosciences and Caribou Biosciences. Direct peers are Kyverna Therapeutics, Fate Therapeutics, Cabaletta Bio and Nkarta Therapeutics.
Does Artiva Biotherapeutics have an API?
No public API is recorded for Artiva Biotherapeutics.
What industry is Artiva Biotherapeutics in?
Artiva Biotherapeutics's product category is Allogeneic NK Cell Therapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.